Abstract Details

Title Parity Associated with Long-Term Disease Progression in Women with Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P02 - (-)

Poster/Presentation
Number 130

Objective

Background BACKGROUND: Pregnancy in MS is marked by a decrease in number of relapses with a corresponding rebound in the first months postpartum. Because MS most often occurs during childbearing years, it is of great importance to investigate the long term effects pregnancy has on MS disease course. Results of previous studies on the long term effects of parity on disease progression are controversial.

Design/Methods DESIGN/METHODS: All subjects were part of the New York State Multiple Sclerosis Consortium (NYSMSC) registry. 1195 parous and 328 nulliparous women with clinically definite MS age 45 or older were analyzed to determine the time to disease progression. A Cox proportional hazards model was used to examine the effect of parity on time from MS disease onset to Expanded Disability Status Scale (EDSS) 6, while adjusting for confounding factors.

Results RESULTS: Of our sample of 1523 women, the average disease duration was 18.1 years. In the parous group, 23.1% reached EDSS 6, while 26.5% of the nulliparous women reached this disability milestone during follow-up. The Cox survival curves between parous and nulliparous women were significantly different (HR=.68, CI=.53-.87, p=.002), with parous women showing a longer time to reach the disability outcome.

Conclusions CONCLUSIONS: Our results indicate that parous women take a longer time to reach EDSS 6, compared to nulliparous women, suggesting a long term parity benefit. Further studies are necessary to clearly confirm this data as disease specifics may influence a patient to become or not pregnant.

Authors/Disclosures
Barbara Teter, PhD MPH (SUNY-University of Buffalo Neurology) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Channa Kolb, MD	No disclosure on file
	No disclosure on file
Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo)	Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH.

��ɫ��

��ɫ��